CA-GLOBALLOGIC-INC.
GlobalLogic Inc. ,1 a Hitachi Group company and leader in Digital Engineering, today announced the availability of its enhanced Microservices Accelerator, a comprehensive and pluggable digital microservices development platform. Developed by GlobalLogic, this technology is used in conjunction with the company’s Digital Engineering services to greatly simplify and accelerate the design, configuration, and deployment of Microservices platforms – which are the most commonly deployed architectures in creating new digital experiences.
Notably, the Microservices Accelerator is currently the foundation platform for many GlobalLogic clients including EyeCare Partners , the leading healthcare service provider for optometry and ophthalmology; Petplan , the most comprehensive pet health care insurance in North America; and DISA Global Solutions , the leading provider of safety, compliance, and screening services.
Part of GlobalLogic’s Digital Accelerators product offerings, the Microservices Accelerator provides a complete solution that includes a project configurator and a set of pluggable modules that perform the most common Non-Functional Requirements (NFRs) required by any microservices-based deployment. The latest release introduces advanced capabilities including CloudEvents support, security framework upgrades, and ETag support to enhance caching capabilities.
Digital Accelerator Key Value Proposition
Driving the accelerator’s development were Independent Software Vendors (ISVs), enterprises, and startup company needs. As more companies move their product offerings to cloud-native platforms, developers seek codified tools that can efficiently address and automate common, time-consuming processes. Early results have shown a savings of up to 75 person months for a typical large-size deployment project, which means significantly reduced time to market, a more reliable and repeatable process, and increased ROI.
“Having deployed many such platforms over the last couple of years, GlobalLogic has established a strong body of knowledge that we have included in this toolset — ranging from enterprise-scale capabilities to best practices. Our clients are already shaving off months from the bootstrap, and reducing overall implementation costs and effort with our solution,” said Piyush Jha , SVP & Chief of Technology and Strategy (APAC), GlobalLogic.
“Microservices is a great architectural paradigm that takes modularity to the next level and, in many ways, is fundamental for achieving the massive scale requirements of modern software,” said Deepak Gupta , SVP & Global Head of Technology Practices, GlobalLogic. “This accelerator is an out-of-box solution that allows engineers to set up complex architectures in a single day, rather than the months typically required. Moreover, it provides a required guardrail to operate within, and reduces the possibilities of human error — which is essential to being successful with this programming paradigm.”
Inter-Company Deployment
As part of Hitachi’s acquisition of GlobalLogic, the accelerator technology will be utilized in Hitachi's services and solutions going forward.
“Hitachi Application Services Division is excited to leverage the GlobalLogic Accelerators in its service delivery schema,” said Emi Goto, Senior Director, Application Services Division, Hitachi, Ltd. “The growth of our Lumada business will be accelerated in the expanding Digital Transformation market by combining the innovativeness of GlobalLogic's Experience Design and Chip-to-Cloud software engineering with Hitachi's enterprise application delivery experiences in mission critical systems.”
GlobalLogic’s Microservices Accelerator supports both containers and functions as a service-based deployment model across cloud hyperscalers Microsoft Azure, AWS, and Google Cloud Platform (GCP).
About GlobalLogic
GlobalLogic (www.globallogic.com ) is a leader in digital engineering. We help brands across the globe design and build innovative products, platforms, and digital experiences for the modern world. By integrating experience design, complex engineering, and data expertise – we help our clients imagine what’s possible and accelerate their transition into tomorrow’s digital businesses. Headquartered in Silicon Valley, GlobalLogic operates design studios and engineering centers around the world, extending our deep expertise to customers in the automotive, communications, financial services, healthcare and life sciences, manufacturing, media and entertainment, semiconductor, and technology industries. GlobalLogic is a Hitachi Group Company.
GlobalLogic is a trademark of GlobalLogic. All other brands, products or service names are or may be trademarks or service marks of their respective owners.
1 July 14, 2021 News Release "Hitachi Completes Acquisition of GlobalLogic” https://www.hitachi.com/New/cnews/month/2021/07/f_210714.pdf
View source version on businesswire.com: https://www.businesswire.com/news/home/20211109005358/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom